| 2016-11-30 08:02:16|
TROV 08:02 11/30 11/30/16
Trovagene, Boreal Genomics announce strategic partnership
Trovagene announced it has entered into a long-term Supply and Distribution Agreement with Boreal Genomics, merging their respective technologies to co-develop urine and blood ctDNA assay kits. Through this partnership, the companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine and low-cost urine and blood ctDNA assay for next generation sequencing platforms run by laboratories of Research Institutions, Cancer Centers, and service facilities around the world. Trovagene and Boreal have each contributed proprietary technology and methods to enhance ctDNA detection capabilities from urine and blood to develop a series of cancer-specific multigene panels planned for launch in 2017. Initially, the panels will be designed to cover National Comprehensive Cancer Network listed clinically actionable mutations with industry-leading sensitivity for which there are targeted therapies or treatment options available. The partnership's goal is to address a gap between single-gene PCR assays that can be limited by sample availability and expensive, broad, multi-gene panels hindered by low clinical sensitivity for mutation detection. The companies intend to develop additional panels throughout the partnership, and Trovagene plans to globally distribute the assay kits for use on the Boreal OnTarget system in blood and exclusively in urine. Trovagene's initial research-use-only proprietary kits will include a urine collection kit, a urine extraction kit and a mutation enrichment kit, along with the Boreal OnTarget system.